Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online August 31, 2006
Stem Cells Vol. 24 No. 12 December 2006, pp. 2888 -2890
doi:10.1634/stemcells.2006-0387; www.StemCells.com
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2006-0387v1
24/12/2888    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berger, M. G.
Right arrow Articles by Boiret-Dupre, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berger, M. G.
Right arrow Articles by Boiret-Dupre, N.

TRANSLATIONAL AND CLINICAL RESEARCH

Cell Culture Medium Composition and Translational Adult Bone Marrow-Derived Stem Cell Research

Marc Gabriel Berger, Richard Veyrat-Masson, Chantal Rapatel, Stéphane Descamps, Jacques Chassagne, Nathalie Boiret-Dupre

CHU Clermont-Ferrand, GECOM, Hématologie Biologique, Hôtel-Dieu, Boulevard Léon Malfreyt, 63058 Clermont-Ferrand Cedex 1, France

Key Words. Clinical translation • Mesenchymal stem cells • Ex vivo expansion • Culture

Correspondence: Marc G. Berger, M.D., Ph.D., Groupe d'Etude des Cellules d'Origine Médullaire (GECOM), Hématologie Biologique, Hôtel-Dieu, Boulevard Léon Malfreyt, 63058 Clermont-Ferrand Cedex 1, France. Telephone: 33 4 73 75 06 82; Fax: 33 4 73 75 06 83; e-mail: mberger{at}chu-clermontferrand.fr

Received on June 26, 2006; accepted for publication on August 22, 2006.

First published online in STEM CELLS EXPRESS  August 31, 2006.


For most therapeutic strategies using MSC, the preliminary amplification is carried out in media containing fetal calf serum (FCS). The theoretical health risk of using a xenogenic serum, a recent practice for which we have limited data, cannot be underestimated, while amplification using human serum (HS) remains controversial. At present, the available information on multipotentiality, self-renewal, and transplantability does not permit the selection of FCS rather than HS. Cellular modifications observed during cell passage seem to indicate a gradual impairment of cells in relation to native MSC, suggesting the making of short cell cultures without necessarily trying to reinfuse a high number of MSC in patients. With this approach, the volume of HS required would remain limited. While clinical studies have already started, many problems remain, such as evaluating the quality of the initial mesenchymal compartment and the biological properties of the cell suspension with FCS compared to those with HS, and depending on culture time.




This article has been cited by other articles:


Home page
 Stem CellsHome page
F. Mannello and G. A. Tonti
Concise Review: No Breakthroughs for Human Mesenchymal and Embryonic Stem Cell Culture: Conditioned Medium, Feeder Layer, or Feeder-Free; Medium with Fetal Calf Serum, Human Serum, or Enriched Plasma; Serum-Free, Serum Replacement Nonconditioned Medium, or Ad Hoc Formula? All That Glitters Is Not Gold!
Stem Cells, July 1, 2007; 25(7): 1603 - 1609.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.